Lonza
About Lonza
Categories

-
US
-
2015On CPHI since
-
5000+Employees
Company types
Meet us at
CPHI North America 2023
Pennsylvania Convention Center, Philadelphia
April, 25-27, 2023
Products from Lonza (5)
-
Product Active Pharmaceutical Ingredients and Intermediates
We provide customized chemical synthesis for active pharmaceutical ingredients from concept to commercial supply.
We are an industry-leading integrated development and manufacturing service provider for small molecule drug substances and their intermediates.
Chemistry is c... -
Product Highly Potent API Handling
HPAPI product handling from concept to commercial-scale manufacturing
Utilizing a combination of technology, infrastructure and expertise, we provide you with seamless, flexible HPAPI development and manufacturing tailored to your specific needs and resulting in reduced program timelin... -
Product Bioavailability Enhancement - Oral Drug Products and Intermediates
The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing addressing low solubility, low bioavailability and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and... -
Product Inhalation Formulation Services
Inhaled drug products for nasal or pulmonary delivery continue in popularity due to the prevalence of respiratory diseases around the globe. Additionally, the lung’s absorptive capacity continues to be explored as an attractive delivery point for both local and systemic applications. Particle engineering, ... -
Product Microreaction Technology
Use of Microreaction Technology (MRT) may lower product cost of goods and increases yield and throughput of a manufacturing facility. This technology is able to perform hazardous, high temperature and pressure reactions, as well as those containing unstable or extremely reactive elements. Using MRT, these ...
Lonza Resources (8)
-
News Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing
The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies -
Brochure Presentation: Achieving Bioavailability Enhancement for Poorly Soluble Compounds
A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. In this on-demand webinar, hear about some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study is presented. -
News Lonza Switzerland site to undergo expansion of microbial development capabilities
The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects -
Whitepaper White Paper: SimpliFiH®️ Solutions for Accelerated Pharmaceutical Development
With the pharmaceutical industry’s focus on accelerating all aspects of drug discovery and development, it is crucial to reduce the time from initial product concept to first-in-human clinical completion. Numerous factors can slow this process, but challenges can be overcome by aligning with a single, integrated Contract Development and Manufacturing Organization (CDMO) to reduce the time, complexity, risks, and costs associated with engaging multiple partners. -
News Lonza boosts exosome capability with Codiak BioSciences facility acquisition
The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies -
Video Lonza
Enabling a healthier world. -
News Lonza to establish multi-product fill and finish line in China
The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches -
News Tech transfer: a many-layered artform that demands precision and communication
Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver. What are the latest innovations to solve tech transfer challenges?
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance